Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Implications of EGFR inhibition in ovarian cancer cell proliferation.

Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, Lea JS.

Gynecol Oncol. 2008 Jun;109(3):411-7. doi: 10.1016/j.ygyno.2008.02.030.

PMID:
18423824
2.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

3.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

4.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
6.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

7.

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.

Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.

Cancer Chemother Pharmacol. 2010 Jul;66(2):381-8. doi: 10.1007/s00280-009-1174-7. Epub 2009 Nov 18.

PMID:
19921194
8.
9.

Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.

Bijman MN, van Berkel MP, Kok M, Janmaat ML, Boven E.

Anticancer Drugs. 2009 Jul;20(6):450-60. doi: 10.1097/CAD.0b013e32832afc24.

PMID:
19369859
11.

The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.

Bolitho C, Hahn MA, Baxter RC, Marsh DJ.

Endocr Relat Cancer. 2010 Oct 5;17(4):929-40. doi: 10.1677/ERC-10-0107. Print 2010 Dec.

12.

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E, Shimizu E.

Cancer Biol Ther. 2012 Apr;13(6):369-78. doi: 10.4161/cbt.19238. Epub 2012 Apr 1.

PMID:
22313637
13.
14.

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.

Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M.

Cancer Res. 2005 Apr 15;65(8):3003-10.

15.

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S.

Lung Cancer. 2012 Dec;78(3):193-200. doi: 10.1016/j.lungcan.2012.08.012. Epub 2012 Sep 15.

PMID:
22985911
16.

Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.

Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P.

Clin Cancer Res. 2005 Oct 15;11(20):7480-9.

17.

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.

Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J, Rolser RL, Li Y, Steiner P, Bassi R, Hicklin DJ, Hadari YR.

Mol Cancer Ther. 2007 Oct;6(10):2642-51. Epub 2007 Oct 3.

18.

Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.

Amaro A, Mirisola V, Angelini G, Musso A, Tosetti F, Esposito AI, Perri P, Lanza F, Nasciuti F, Mosci C, Puzone R, Salvi S, Truini M, Poggi A, Pfeffer U.

Eur J Cancer. 2013 Oct;49(15):3353-65. doi: 10.1016/j.ejca.2013.06.011. Epub 2013 Jul 9.

PMID:
23849826
19.

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3802-12. Erratum in: Cancer Res. 2010 Jan 15;70(2):852-3.

20.

PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).

Shien T, Doihara H, Hara H, Takahashi H, Yoshitomi S, Taira N, Ishibe Y, Teramoto J, Aoe M, Shimizu N.

Breast Cancer. 2004;11(4):367-73.

PMID:
15604992

Supplemental Content

Support Center